- INmune
Bio is at the vanguard of reprogramming the innate immune system for the
treatment of disease
- The
company’s focus is on modulating components of the innate immune system to
treat cancer and Alzheimer’s disease
- INmune
Bio’s drug candidates include INKmune, INB03 and XPro1595
INmune Bio Inc. (NASDAQ: INMB) is a diversified,
clinical-stage biotechnology company headquartered in La Jolla, California. The
company is hoping to develop new immunotherapies that reprogram patients’
innate immune systems to allow the immune systems to fight cancer and
Alzheimer’s disease. INmune drug candidates INKmune and INB03 may be used to
treat cancer, while XPro1595 targets neuroinflammation as a cause of
Alzheimer’s disease.
INmune Bio’s vision is to become the leader in reprogramming
the innate immune system for the treatment of disease. Innate is an immediate,
nonspecific, initial response that serves as a first line of defense against
infection and cancer. Most drug-development programs concentrate on the
adaptive immune response and ignore innate immunity. INmune Bio harnesses the
innate immune system with a targeted biomarker approach.
The company’s INKmune drug is a biologic therapy. INKmune
primes NK cells to eliminate minimal residual disease, which is a major cause
of cancer relapse and death. NK cells play a vital role in preventing cancer.
Later this year, the company expects to begin enrolling patients in a phase
I/II trial for women with relapsed refractory ovarian cancer.
INKmune is delivered by simple IV infusion, allowing for the
delivery of critical priming signals to patients’ resting NK cells. Once in the
system, INKmune encounters resting NK cells. The interaction converts NK cells
to primed NK cell (“PiNK”), much like an on-off switch. PiNK then remain primed
until they contact and kill cancer cells (http://ibn.fm/zb0GM).
INmune Bio’s INB03 is a protein biologic. The company
believes that INB03 could have numerous beneficial effects in patients with
cancer. INmune Bio’s initial emphasis is on its ability to inhibit the
proliferation and function of myeloid-derived suppressor cells (“MDSC”). By
preventing the proliferation and function of MDSC, the company believes that
patients will have a stronger immune response to cancer cells.
INmune Bio also believes that INB03 treatment may help
patients better respond to other cancer treatments, including immunotherapy.
INB03 is a PEGylated protein therapeutic administered as a once-weekly
subcutaneous injection, similar to an insulin shot (http://ibn.fm/Dql3j). This
summer, the INB03 program will transition into a combination therapy clinical
program to prepare for a phase II trial to research patients’ resistance to
checkpoint inhibitors because of increased MDSC.
The company’s XPro1595 is a protein biologic that targets
soluble TNF (“sTNF”). XPro1595 may trigger many beneficial effects in patients
with Alzheimer’s disease by reducing neuroinflammation. XPro1595 targets the
microglial immune cells of the brain, which are responsible for
neuroinflammation and are activated in many Alzheimer’s disease patients.
INmune Bio continues to develop its product platforms that
use a precision therapy approach. The company offers investors the potential
for significant ROI as it targets large markets with unmet needs. With its
programs in oncology and neurodegenerative disease, INmune Bio is focusing on
multiple opportunities that provide sum-of-parts value.
For more information, visit the company’s website at www.INmuneBio.com
NOTE TO INVESTORS: The latest news and updates relating
to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
